Timing Is Everything…Or Is It?

The market's rally, especially in small-cap, continued this past week and Tailwinds' stocks participated along with the broader indexes. In particular, performance of our...

Mustang Bio Announces Positive Opinion from the European Medicines Agency on Orphan Drug Designation...

Tailwinds' Take: Mustang continues to march towards successfully obtaining approval for their novel drugs. We believe MBIO is deeply discounted relative to the value...

Mustang Bio and Minaris Regenerative Medicine Sign Technology Transfer and GMP Manufacturing Agreement for...

Tailwinds' Take: planned expansion into Europe is a positive for this program. We continue to be very supportive of MBIO heading into their data...

Checkpoint Therapeutics Announces Presentation of Updated Cosibelimab Lung Cancer Results at the Society for...

Tailwinds' Take: very positive results for a drug that could be equally efficacious and lower cost in a $10B market. A Fortress Bio (FBIO)...

Moving Week

What do Donald Trump and I have in common? We are both in the process of moving... This week we found out that Joe Biden...

Mustang Bio Announces MB-106 Data Selected for Presentation at the 62nd American Society of...

Tailwinds' Take: very positive that ASH has accepted this data. Two patients with complete response out of four is excellent data. MBIO stock is...

Mustang Bio Announces Initial Phase 1 Data on MB-105 for Patients with PSCA-positive Castration...

Tailwinds' Take: positive early stage results in one patient bode well for this novel solid-tumor CAR-T treatment. Success here could be worth several billions...

Time for Small Cap to Shine?

Small and micro-cap stocks have underperformed the market for quite a while now. Since I started Tailwinds in August of 2016, the Russell 2000...

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

Tailwinds' Take: very negative news for ATXI and parent company FBIO. Delayed onset of action had been a concern that was downplayed by management....

This Week In Moab

Having written a newsletter for almost 200 consecutive weeks, I didn't want to miss this week. But, I am mountain biking in Moab Utah,...

Mustang Bio Announces MB-105 Data Selected for Presentation at the Virtual 27th Annual Prostate...

Tailwinds' Take: this is exciting news for MBIO. City of Hope controls the data and their decision to release it implies positive data. Mustang...

The Final Push…

Like the debate, 2020 has been a sh**-show. Pandemics, political divisiveness, fires...it's not been a beach party to say the least. Yet, here we stand...

Mustang Bio Announces First Patient Dosed in Multicenter Phase 1/2 Clinical Trial of MB-102...

Tailwinds' Take: with their own manufacturing facility, MBIO has excellent potential in CAR T therapy development. This is a "momentous occasion" for the Company...

Wrapping Up A Chaotic Week

Markets were very volatile this past week, trading back and forth like a game of ping-pong. There's little doubt in my mind that the...

West Bound and Down

After fortuitously sheltering in place on the east coast for seven weeks, we are heading back for CA this week. We seem to have,...

Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous...

Tailwinds' Take: very positive results for CKPT, which is a partner company of Fortress Bio (FBIO). This is a potentially disruptive drug for a...

Fortress Biotech Announces Initiation of Phase 3 Studies of CAEL-101 in AL Amyloidosis

Tailwinds' Take: long-term survival data supports the thesis for CAEL-101 demonstrating efficacy in phase 3, which would most likely trigger the acquisition by Alexion....

Under The Radar…Key Data-Points From The Last Week That Nobody Really Noticed

The easiest way to make money in the market is trading off of insider information. It is also highly illegal, will put you in...

Avenue Therapeutics Announces Publication of a Review of IV Tramadol

Tailwinds' Take: more endorsement of a product whose PDUFA date (Oct. 10th) is rapidly approaching. We continue to believe IV Tramadol will get approval...

Mustang Bio Announces Orphan Drug Designation for MB-107 for the Treatment of X-linked Severe...

Tailwinds' Take: MBIO continues to execute on the regulatory pathway for their drugs. We continue to believe the stock is significantly undervalued. WORCESTER, Mass., Sept....

Mustang Bio Announces Rare Pediatric Disease Designation for MB-207 for the Treatment of X-linked...

Tailwinds' Take: the MBIO platform is greatly undervalued in our opinion. This gives them a second program with a rare pediatric disease designation. And,...

Goodbye August (almost)…

Okay, I know it's not the official end of August...that takes place on Monday. However, due to the fact that the month is basically...

Fortress Biotech Announces Positive Topline Clinical Efficacy Results for CUTX-101, Copper Histidinate, for the...

Tailwinds' Take: the data strongly suggest that CUTX-101 should receive FDA approval sometime next year. Very positive for FBIO. NEW YORK, Aug. 28, 2020 (GLOBE...

Fortress Biotech Announces $60 Million Loan Agreement with Oaktree Capital Management

Tailwinds' Take: this is very positive news as we believe this loan, coupled with the recent preferred financing, will allow FBIO to cease stock...

Mustang Bio Announces Rare Pediatric Disease Designation for MB-107 for the Treatment of X-linked...

Tailwinds' Take: this is good news in that the FDA obviously sees the benefit of this drug, but also in that they are now...

This Week at Tailwinds

Stocks continued to climb the proverbial wall of worry last week, with the S&P briefly managing to touch an all-time high and the Russell...

Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley FBR on...

Tailwinds' Take: a must attend for investors interested in a diversified biotech with a deeply discounted valuation relative to the numerous major catalysts and...

Fortress Biotech Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

Tailwinds' Take: core derm business remains weak during Covid-19, but Fortress continues to execute in many other areas. Lots of catalysts coming up in...

OnTrak For A Great Year

Telehealth was the all the rage this past week. First The Centers for Medicare & Medicaid Services (CMS) is proposing changes to expand telehealth...

Checkpoint Therapeutics to Present Cosibelimab Interim Results from Registration-Enabling Trial at ESMO Virtual Congress...

Tailwinds' Take: this data, if it continues to show the efficacy demonstrated in earlier interim results, could position CKPT for an BLA submission with...

Random Thoughts on a Number of Stocks…

There's certainly a lot going on in the world at large right now and none of it seems too good. Covid-19 refuses to go...

Avenue Therapeutics Announces Publication of Phase 3 Bunionectomy Study Results

Tailwinds' Take: while not "new news", this provides further confidence in the odds of approval for IV Tramadol. Peer reviewed data also can help...

Previewing the 2nd Half of 2020…and Other Updates From The Week

Greetings from...wait for it...Ashland Oregon. Yes, it was so good, we came back for more. The weather here is great, the riding is outstanding...

Happy 4th of July…A Review of June and Other Notes

With June closing out, we can now reflect on what was the best quarter the stock market has seen since the turn of the...

This Week at Tailwinds…Scratching My Head

Perhaps it's because I've not seen the barber during the pandemic, but the market has me left me scratching my head. Some recent stock...

Mustang Bio Announces Pricing of Public Offering of Common Stock

Tailwinds' Take: I don't believe that Mustang could have had much better timing in getting this deal done. Fortress Bio (FBIO) is the largest...

Avenue Therapeutics Announces Publications in Peer-Reviewed Journals

Tailwinds' Take: these results are not at all unexpected, but they add further confirmation to the thesis that Avenue's IV Tramadol will be approved...

June Preview…Plus Much More!

May was another strong month for the market as the stimulus package and expectations for a strong re-opening of the economy kept the rebound...

Moneyball for Biotech

Moneyball: The Art of Winning an Unfair Game is a book by Michael Lewis about the Oakland Athletics baseball team and its general manager Billy Beane. The focus of the...

This Week’s Recap: Skinny Trails, Anixa Looks Primed, Atomera Launching

As most readers know by now, I love mountain biking. It's great exercise and there's a tremendous thrill to hitting a difficult stretch of...

Bada Bing Bada Boom

As if on cue, the market took a turn lower last week. This will be but a quick note on the market, as I'm...

Fortress Biotech Reports Record First Quarter 2020 Financial Results and Recent Corporate Highlights

Tailwinds' Take: Fortress has a whole host of catalysts coming during 2020, as detailed in this shareholder update. Importantly, by breaking out the non-GAAP...

The Week In Review

The market continues to ignore my bearish calls and, instead, keeps chugging higher. I'm at a loss to explain this, as are most professional...

Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide...

Tailwinds' Take: this is another potential coup by Fortress, as their business model involves partnering on and developing novel therapies. Their ability to create...

Checkpoint Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights

NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the...

The Eye Of The Storm…This Week In Tailwinds’ World

Well, I've been expecting it and it appears that it's here. The market put up one of its best months ever in April, but...

Avenue Therapeutics Announces Presentation of IV Tramadol E-Posters

Tailwinds' Take: FBIO owns ~30% of Avenue. This news, while not unexpected, further cements the case for IV Tramadol being a well-used medication post...

Mustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107...

Tailwinds' Take: a positive step towards approval of this needed therapy. Fortress Bio (FBIO), the parent of Mustang, has many such catalysts going forward...

Saturday Morning Ramblings…

Another great week in the market. The economy is in free-fall, unemployment is skyrocketing and stocks can't stop going up. How is this possible?...

This Week In MicroCap

It was certainly a great week for the market as a number of positive factors contributed to the continuation of what is a very...

IF Alpha?

My biggest concern last fall was, "what if Bernie gets into office?" This fear was driven partially by the fact that the market would...

Building Our Case for Fortress (FBIO)

In this, our third article about Fortress Biotech (FBIO), we discuss the value of two in-house subsidiaries, Journey Medical and Caelum BioSciences. Both entities...

Take a Deep Breath…Updates on the Market and Several Stocks

My Take on The Market This was a good week in the market, which was a welcome relief. We had a big bailout announced by...

There’s Blood In The Streets…

Normally I love my Saturday mornings. This is when I write the weekly newsletter and it gives me a chance to review the prior...

Fortress Biotech Reports Record Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate...

Tailwinds' Take: 2019 was a very impressive year of accomplishment for FBIO. The stage is set for a big 2020 as well, with many...

It’s Definitely a Beer Market

Sometimes a typo can hit the sweet spot, right? When I got the text that we're entering a beer market...well, let's just say that...

Checkpoint Therapeutics Reports Full-Year 2019 Financial Results and Recent Corporate Highlights

Tailwinds' Take: with a pivotal trial ongoing, CKPT is another hidden gem in FBIO's vault. Funded through YE 2021 with hopes for BLA submission...

February Recap and More Thoughts From Last Week…

As I look out my office window here in NorCal and see the blossoms on the tree, it's tough to remember that it's still...

Fortress Biotech, Chapter 2: Mustang Bio

Fortress Biotech (FBIO) has an interesting business model that involves an operating subsidiary focused on dermatology and multiple other partially owned subsidiaries that are...

Mustang Bio Announces First Subject Treated in Phase 1/2 Trial with the Optimized CD20-targeted...

Tailwinds' Take: very exciting news for FBIO's 1/3 owned subsidiary, Mustang Bio. Expect to see the street taking targets up for MBIO, which is...

Thoughts From The Last Week…

Lots going on in Tailwinds' universe recently. Here I recap conversations and observations from the prior week's trading... This screen shot says it all...if Druck...

Avenue Therapeutics Announces New Drug Application for IV Tramadol Accepted for Review by FDA

Tailwinds' Take: ATXI is one step closer to being acquired by Cipla. We believe FDA acceptance is a very likely outcome for IV Tramadol...

Slogging Through Winter

I was skiing outside Seattle last weekend. Steven's Pass ski resort, to be precise. They have gotten a lot of snow up there this...

Wasn’t That An Amazing Sunset?

On Thursday this week, as we finished dinner I looked out the window and the sky was on fire. It was quite possibly the...

Understanding Fortress Biotech Part 1, Avenue Therapeutics

With a plethora of balls in the air, Fortress Biotech is a very difficult company to value. Their financials, being a combination of the...

Early Returns

New Years always brings out the prognosticator in all of us. Everyone likes to predict what the market will do, what sectors will shine...

Fortress Biotech Announces Rare Pediatric Disease Designation for CUTX-101 for the Treatment of Menkes...

Tailwinds' Take: Fortress' value add is in finding underdeveloped drugs that have excellent scientific research and bringing them through the FDA process and to...

Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell...

Tailwinds' Take: the many shots on goal under the FBIO umbrella is one of the most compelling aspects of the company. This is great...

Journey Medical Corporation Recaps 2019 Growth

Tailwinds' Take: Journey is growing rapidly as they execute on the overall strategy of FBIO; licensing low-risk products and bringing them to market. This...

What to Expect When Everyone’s Expecting (An Up Market)

What a difference a year makes. Christmas 2018 marked a time of anguish for investors. The market was in the toilet and, for us...

Visions of 2020

This last week was actually a very good week for the Tailwinds' portfolio. Despite the overall quiet of a holiday week (or maybe because...

Fortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca and Cincinnati Children’s Hospital Medical...

Tailwinds' Take: this deal demonstrates the effectiveness of FBIO's business model. They are accumulating a plethora of interesting drugs under their umbrella.  NEW YORK, Dec....
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.